172376-39-5

Basic information

• Product Name: (3R,4S)-4-(3-isopropoxyphenyl)-1,3-dimethyl-piperidin-4-ol
• Synonyms: (3R,4S)-4-(3-Isopropoxyphenyl)-1,3-dimethylpiperidin-4-ol
• CAS NO: 172376-39-5
• Molecular Formula: C₁₆H₂₅NO₂
• Molecular Weight: 263.38
• Mol File: 172376-39-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 388.6°C at 760 mmHg
• Flash Point: 188.8°C
• Density: 1.034g/cm³
• Vapor Pressure: 9.8E-07mmHg at 25°C
• Refractive Index: 1.524
• PKA: 14.09±0.40(Predicted)
• CAS DataBase Reference: (3R,4S)-4-(3-isopropoxyphenyl)-1,3-dimethyl-piperidin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,4S)-4-(3-isopropoxyphenyl)-1,3-dimethyl-piperidin-4-ol(172376-39-5)
• EPA Substance Registry System: (3R,4S)-4-(3-isopropoxyphenyl)-1,3-dimethyl-piperidin-4-ol(172376-39-5)

Safety Data

• Hazardous Substances Data: 172376-39-5(Hazardous Substances Data)

Usage

Description

(3R,4S)-4-(3-isopropoxyphenyl)-1,3-dimethyl-piperidin-4-ol is a chemical compound belonging to the class of piperidine derivatives. It is characterized by a molecular formula of C17H27NO2 and features a piperidine ring with a 3-isopropoxyphenyl group and a hydroxyl group on the 4th carbon. (3R,4S)-4-(3-isopropoxyphenyl)-1,3-dimethyl-piperidin-4-ol is known for its stereoisomers, with the (3R,4S) configuration being the most extensively studied. Its structural features and functional groups suggest potential pharmaceutical applications, although further research is required to determine its biological activity and possible uses in the medical field.

Uses

Used in Pharmaceutical Applications:
(3R,4S)-4-(3-isopropoxyphenyl)-1,3-dimethyl-piperidin-4-ol is used as a potential pharmaceutical agent due to its unique structural features and functional groups. (3R,4S)-4-(3-isopropoxyphenyl)-1,3-dimethyl-piperidin-4-ol's specific configuration and the presence of a piperidine ring make it a candidate for further research and development in the medical industry.
Used in Drug Development:
In the field of drug development, (3R,4S)-4-(3-isopropoxyphenyl)-1,3-dimethyl-piperidin-4-ol is used as a starting point for the synthesis of new drugs. Its structural properties may allow for the creation of novel compounds with specific therapeutic effects, pending further investigation into its biological activity.
Used in Chemical Research:
(3R,4S)-4-(3-isopropoxyphenyl)-1,3-dimethyl-piperidin-4-ol serves as a subject of interest in chemical research. Its stereochemistry and functional groups make it a valuable compound for studying the effects of stereoisomerism on chemical reactivity and potential applications in various industries.

Upstream product

• 4629-80-5 1,3-dimethyl-4-piperidinone 
• 131738-73-3 3-(isopropyloxy)phenylbromide 
• 591-20-8 3-Bromophenol 

Downstream Products

• 1585988-79-9 3-methyl-1-(3-phenylpropyl)-4-(3-(propan-2-yloxy)phenyl)piperidine 
• 1027912-58-8 C₁₆H₂₃NO 
• 149541-62-8 C₁₉H₂₉NO₄ 
• 149541-62-8 C₁₉H₂₉NO₄ 
• 143919-32-8 (R)-1,2,3,4-tetrahydro-1,3-dimethyl-4-<3-(1-methylethoxy)phenyl>pyridine 
• 143919-34-0 (3R,5R)-1,3,4-trimethyl-4-<3-(1-methylethoxy)phenyl>piperidine 
• 1184775-81-2 C₁₇H₂₇NO*C₂₀H₁₈O₈ 
• 145678-86-0 (3R,4R)-3,4-dimethyl-4-<3-(1-methylethoxy)phenyl>piperidinecarboxylic acid phenyl ester 
• 119193-19-0 3-[(3R,4R)-3,4-dimethylpiperidin-4-yl]phenol 
• 170098-39-2 methyl (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinepropanoate 
• 170098-29-0 methyl (αS,3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-α-(phenylmethyl)-1-piperidinepropanoate 

Relevant articles and documents

Synthesis and characterization of all possible diastereoisomers of alvimopan

Isolation of all possible diastereomers of alvimopan 1 was found to be challenging. In order to perform cut off studies during analytical method development, it was mandatory to synthesize and characterize all the diastereomeric impurities. Here in, our efforts toward the synthesis and isolation of alvimopan (1) diastereomers are discussed.

Solid dispersions of opioid antagonists

Solid dispersions of stable, amorphous opioid antagonists, particularly [[2(S)-[[4(R)-(3-hydroxyphenyl)-3(R),4-dimethyl-piperidinyl]methyl]-1-oxo-3-phenylpropyl]amino]acetic acid, with improved water solubility and bioavailability are disclosed. Also disclosed are methods of preventing or treating a side effect associated with an opioid. In addition, methods of treating or preventing pain, ileus, and opioid bowel dysfunction are disclosed.

Compositions containing opioid antagonist

Compositions containing opioid antagonists, particularly alvimopan and its active metabolite, with improved solubility and bioavailability for oral or parenteral administration, injectable dosage formulations, kits, and methods of making and using same are disclosed. In preferred embodiments, invention provides injectable formulations containing opioid antagonists, particularly alvimopan and its active metabolite, having low solubility that may be readily prepared, are stable during storage, and provide maximum levels of opioid antagonists when administered parenterally, particularly via injection. The results are achieved by a combination of processing techniques and component selection.